Patients
Built around the patients we serve
People living with severe autoimmune disease often have to wait years — or even a lifetime — for effective therapies targeted to their condition. Priovant exists to change that. We are committed to developing new medicines for autoimmune diseases with significant unmet need, delivering life-changing options for patients who have previously been overlooked and underserved. Listening to, understanding the experiences of, and ultimately generating results for these patients drives everything that we do.
Candice, living with dermatomyositis
Lead disease area
Dermatomyositis
Glennis, living with DM
Dermatomyositis (DM) is an autoimmune disease that causes extensive, painful, and itchy skin rashes, and progressive muscle weakness that can make everyday tasks — like climbing stairs, carrying groceries, and getting dressed — difficult or even impossible. DM can also affect the lungs, heart, and other organs, and many people living with it rely on long-term, high-dose steroids that carry their own serious health consequences.
For decades, there were no targeted therapies approved for DM. Priovant recently obtained FDA approval for LISRAYA (brepocitinib) following the completion of the largest DM clinical study ever conducted.
To learn more about DM from leading medical experts, and to hear the stories of people living with the disease and their care partners, visit dermatomyositis.com(opens in a new tab).
Voices from the dermatomyositis community
Other disease areas in our development pipeline
Non-Infectious Uveitis
Non-infectious uveitis (NIU) is an inflammatory eye disease that can lead to permanent vision loss and is one of the leading causes of blindness in the United States. Brepocitinib is currently being evaluated in the Phase 3 CLARITY study in NIU, with results expected in the second half of 2026, and has received Fast Track Designation from FDA.
Clinical trial information↗Cutaneous Sarcoidosis
Cutaneous sarcoidosis (CS) produces disfiguring inflammatory skin lesions that can rapidly lead to permanent scarring and destruction of bone, cartilage, and hair. There are no FDA-approved treatment options. Brepocitinib received Breakthrough Therapy Designation from FDA following its successful Phase 2 study in CS and is currently being evaluated in the Phase 3 BEACON+ study.
Lichen Planopilaris
Lichen planopilaris (LPP) is an inflammatory skin disease that causes permanent, scarring hair loss, often accompanied by pain, itching, and burning. It currently has no FDA-approved treatment options. Brepocitinib is being studied in the Phase 2b/3 ALPINE trial for LPP, which began enrolling in March 2026.
Clinical trial information↗